Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs reported a first-quarter 2026 net loss of $14.8 million, slightly wider than $13.7 million a year earlier, as it expanded spending on its lead inflammatory bowel disease candidate SL-325. Research and development expenses rose to $10.9 million, while general and administrative costs were stable at $4.6 million.
Cash and cash equivalents increased to $90.4 million from $54.2 million at year-end 2025, helped by $20.6 million of common stock sales through an at-the-market program and $5.4 million of warrant exercises. Management believes this cash is sufficient to fund operations for at least 12 months as it completes a Phase 1 trial of SL-325 and prepares a Phase 2 trial in Crohn’s disease.
Shattuck Labs, Inc. reported first quarter 2026 results and business updates. The company is running a Phase 1 trial of its lead DR3 blocking antibody SL-325, has completed enrollment in all single- and multiple-ascending dose cohorts, and plans to share detailed data in the second quarter of 2026. Subject to positive Phase 1 data and regulatory alignment, a Phase 2 trial in Crohn’s disease is expected to start in the third quarter of 2026, and a lead DR3-based bispecific antibody has entered IND-enabling activities.
Financially, Shattuck had $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, up from $60.9 million a year earlier. First quarter 2026 research and development expenses were $10.9 million, general and administrative expenses were $4.6 million, and net loss was $14.8 million, or $(0.13) per basic and diluted share. The company expects existing cash, including potential proceeds from outstanding common stock warrants, to fund operations into 2029 based on current plans.
Shattuck Labs, Inc. will hold its 2026 virtual annual stockholder meeting on May 28, 2026 at 11:30 a.m. Eastern Time. Stockholders of record as of April 2, 2026, when 75,581,787 common shares were outstanding, may vote online on several governance and compensation items.
Investors are asked to elect three Class III directors to serve until the 2029 annual meeting, ratify KPMG LLP as independent auditor for the year ending December 31, 2026, and approve a non-binding advisory vote on executive pay and the frequency of future say‑on‑pay votes, where the Board recommends every one year.
The proxy also seeks approval of an amended and restated 2020 Equity Incentive Plan, which would fix the share pool at 14,123,126 shares plus a one-time 1,691,082-share increase and update the automatic annual increase to 4% of total capital stock from 2027 through 2030, helping maintain equity capacity for employees, directors and consultants.
Shattuck Labs, Inc. provides an annual business update focused on its DR3/TL1A antibody platform for inflammatory and immune‑mediated diseases. The company’s lead program, SL‑325, is a high‑affinity DR3‑blocking monoclonal antibody in a randomized Phase 1 SAD/MAD trial in healthy volunteers, with enrollment expected to complete in the second quarter of 2026 and a Phase 2 Crohn’s disease trial planned for the third quarter of 2026.
Preclinical GLP studies in non‑human primates showed full, durable DR3 receptor occupancy at doses as low as 1 mg/kg and a no‑observed‑adverse‑effect level at 100 mg/kg, supporting extended dosing intervals. Shattuck is also advancing SL‑425, a half‑life‑extended DR3 antibody, and multiple preclinical DR3‑based bispecific antibodies, while emphasizing intellectual property, outsourced cGMP manufacturing, and detailed compliance with U.S. and international biologics regulations.
Shattuck Labs, Inc. reported fourth quarter and full-year 2025 results and updated its development and cash outlook. The company is advancing SL-325, a potential first-in-class DR3 blocking antibody, with Phase 1 data expected in the second quarter of 2026 and a Phase 2 Crohn’s disease trial planned for the third quarter of 2026.
R&D expenses fell to $35.3 million in 2025 from $67.2 million in 2024, mainly due to discontinuation of the SL-172154 program and workforce reductions, while G&A decreased to $17.2 million from $19.1 million. Net loss narrowed to $48.8 million, or $0.70 per share, from $75.4 million, or $1.49 per share, in the prior year.
Cash, cash equivalents and short-term investments were approximately $78.1 million as of December 31, 2025, and about $94.5 million as of February 28, 2026 including $21.4 million of gross proceeds from at-the-market stock sales. Based on current plans and assuming full warrant exercise, Shattuck expects its capital to fund operations into 2029.
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting beneficial ownership of 7,373,891 shares of Shattuck Labs Inc common stock, representing 11.7% of the class.
The firm reports sole voting and sole dispositive power over all reported shares and certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Shattuck Labs.
Shattuck Labs, Inc. has set its 2026 annual meeting of stockholders for Thursday, May 28, 2026. The meeting date is more than 30 days earlier than the prior year’s meeting, so previously disclosed deadlines for stockholder proposals and director nominations no longer apply.
The company will provide revised deadlines in connection with the 2026 annual meeting, and any stockholder proposals or nominations must comply with SEC Rule 14a-8 and the company’s Bylaws. Full details will appear in upcoming proxy materials to be filed with the SEC.
Shattuck Labs Chief Medical Officer reports share disposition
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, reported a transaction in the company’s common stock. On 01/25/2026, 3,195 shares of common stock were disposed of in a transaction coded "F" at a price of $4.15 per share. Following this transaction, Pandite beneficially owns 196,219 shares of Shattuck Labs common stock in direct ownership form.